The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastomaMin Pan, Paul Geeleher, William C. Wright et al.|Nature Communications|2021Cited by 95
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell linesGisele Nishiguchi, Zoran Ranković, Shilpa Narina et al.|Nature Communications|2024Cited by 50
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalkConstance Baer, Charles G. Mullighan, Shunsuke Kimura et al.|Nature Genetics|2022Cited by 42
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastomaMin Pan, Paul Geeleher, William C. Wright et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 6
Poster: CLL-156: Novel CCL22 Mutations Drive Chronic Lymphoproliferative Disorder of NK Cells Through Biased GPCR SignalingShunsuke Kimura, Charles G. Mullighan, Constance Baer et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 0